They reported an accuracy of up to 88.7%, with a higher accuracy of 93.2% and 90.9% for Luminal and triple negative breast cancer, respectively, and a lower accuracy of HER2 over-expression breast cancer. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.